AMD

Conditionally accepted by the FDA as EYO-1901, DURAVYU is a tyrosine kinase inhibitor intended to improve signs and symptoms of non-proliferative diabetic retinopathy in the PAVIA trial.

The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene, the company stated in a news release.

The AI-powered model works to detect early signs of glaucoma and makes iHealthScreen the first company to receive 2 US patents for AMD and glaucoma screening devices.

The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.

The South Korean study found that those with age-related macular degeneration may be more at risk of developing some cancers, like renal and thyroid.

Optometry Times chats with Tracy Williams, OD, FAAO, on AMD and low vision's impact on patients' overall health and mental wellness.

New treatments for geographic atrophy coming down the pike has the potential to change eye care providers' approach to identifying and managing the disease.

The clinical-stage biopharmaceutical company is running 2 Phase 3 clinical trials, COAST and ShORe, to assess the efficacy and safety of using combinations of certain drugs to treat wet age-related macular degeneration.

AREDS2 supplementation and close monitoring of gut microbiota may help patients at risk for vision loss.

The study further defined the relationship between delayed rod-mediated dark adaptation and the status of outer retinal bands on optical coherence tomography.

When a patient has low contrast sensitivity, it means they have difficulty perceiving and distinguishing objects or patterns with subtle differences in contrast. This can have several implications for their vision and daily life, since our world is not merely black and white.

The agreement redefines participant requirements and a slightly increased daily release of the drug, which is currently in a Phase 3 clinical trial.

A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.

OCU410 is a modifier gene therapy product candidate being developed by Ocugen for dry AMD.

The study of OliX Pharmaceuticals' investigative property saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

The company announced key secondary endpoints were achieved with both EYP-1901 doses. These include a more than 80% reduction in treatment burden, with nearly two-thirds of eyes supplement-free up to 6 months.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

A rapid-fire, top-level review of what happened in optometry in 2023.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

Optometry Times sat down with Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, to discuss his upcoming presentations at AAOpt.

Prevention should be at the forefront of the discussion.

The FDA determined it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

Clinicians may have difficulty in making a diagnosis.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.